ANAB NASDAQ
AnaptysBio, Inc.
1W: -4.8%
1M: -13.1%
3M: -22.1%
YTD: +61.9%
1Y: +127.7%
3Y: +294.2%
5Y: +166.2%
$48.53
-0.10 (-0.21%)
Weekly Expected Move ±3.8%
$45
$47
$49
$50
$52
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
14 relationships14
As Filer
counterparties named
0
As Counterparty
mentioned by others
5
Rel. Types
2021-10-25
Earliest Filing
2026-03-27
Latest Filing
partner: 6
investor: 3
customer: 3
target: 1
acquirer: 1
Counterparties (Filed by ANAB)
14 relationshipsCompanies named in ANAB's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| First Tracks Biotherapeutics, Inc. | TRAX | target | SpinCo entity being separated from AnaptysBio and issuing stock in a private placement | 2026-03-27 | View |
| EcoR1 Capital Fund Qualified, L.P. | — | investor | Selling Stockholder selling shares in the SpinCo private placement | 2026-03-27 | View |
| Vanda Pharmaceuticals Inc. | VNDA | partner | AnaptysBio granted Vanda an exclusive global license for imsidolimab development and commercialization. | 2025-02-03 | View |
| Centessa Pharmaceuticals (UK) Limited | CNTA | partner | AnaptysBio entered into an exclusive worldwide license agreement for BDCA2 modulator antibody portfolio rights. | 2023-11-27 | View |
| DRI Healthcare Trust | — | acquirer | Acquired all future royalties on Zejula sales from AnaptysBio | 2022-09-12 | View |
| GlaxoSmithKline LLC | — | customer | Pays royalties to AnaptysBio under the Settlement Agreement for Zejula sales | 2022-09-12 | View |
| Tesaro, Inc. | — | customer | Pays royalties to AnaptysBio under the Settlement Agreement for Zejula sales | 2022-09-12 | View |
| Tesaro Development, Ltd. | — | customer | Pays royalties to AnaptysBio under the Settlement Agreement for Zejula sales | 2022-09-12 | View |
| Sagard Healthcare Royalty Partners, LP | — | investor | Partnered with AnaptysBio via a Royalty Purchase Agreement to monetize a portion of future JEMPERLI royalties and milest | 2021-12-01 | View |
| GlaxoSmithKline | GSK | partner | Parent company of Tesaro, Inc. and Tesaro Development, Ltd., holding the Collaboration Agreement with AnaptysBio for JEM | 2021-12-01 | View |
| Sagard Healthcare Royalty Partners, LP | — | investor | AnaptysBio entered into a Royalty Purchase Agreement to monetize future JEMPERLI royalties and milestones. | 2021-10-25 | View |
| GlaxoSmithKline | GSK | partner | Parent company of Tesaro, Inc. and Tesaro Development, Ltd., with whom AnaptysBio has a Collaboration Agreement. | 2021-10-25 | View |
| Tesaro, Inc. | — | partner | Wholly-owned subsidiary of GSK with whom AnaptysBio has a Collaboration Agreement. | 2021-10-25 | View |
| Tesaro Development, Ltd. | — | partner | Wholly-owned subsidiary of GSK with whom AnaptysBio has a Collaboration Agreement. | 2021-10-25 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-21 | Exhibits | View | |
| 2026-08-11 | Shareholder Vote; Exhibits | View | |
| 2026-07-30 | Regulation FD | View | |
| 2026-06-22 | Material Agreement | Agreement | View |
| 2026-05-29 | Regulation FD | View | |
| 2026-05-21 | Bylaws Amendment | View | |
| 2026-05-12 | Earnings Release; Exhibits | View | |
| 2026-03-27 | Material Agreement; Termination of Agreement; Officer/Director Change; Regulation FD; Exhibits | Agreement | View |
| 2026-03-03 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-01-09 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-26 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-21 | Other Events | View | |
| 2025-11-21 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-10 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-14 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-09-29 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-17 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-06-03 | Regulation FD Disclosure; Other Events | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR